Meeting
2022 ASCO Gastrointestinal Cancers Symposium
QoL analysis: A randomized phase 3 study of sequential versus combination treatment in first-line chemotherapy for metastatic colorectal cancer—The C-cubed study.
Authors
Shingo Noura
Department of Surgery, Osaka Rosai Hospital, Sakai, Japan
Shingo Noura , Ryo Inada , Hitoshi Ojima , Takeshi Nagasaka , Hiroaki Tanioka , Yoshinori Munemoto , Yasuhiro Shimada , Keiichiro Ishibashi , Yoshiaki Shindo , Mototsugu Shimokawa , Hideyuki Mishima , Yoshiyuki Yamaguchi , Masazumi Okajima
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
DOI
10.1200/JCO.2022.40.4_suppl.102
Abstract #
102
Poster Bd #
L9
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
CD276-positive circulating endothelial cells in advanced colorectal cancer.
First Author: Elske C. Gootjes
Poster
2018 Gastrointestinal Cancers Symposium
A randomized phase III clinical trial of sequential capecitabine or 5-FU plus bevacizumab (Cape/5-FU+Bmab) followed by Cape/5-FU plus oxaliplatin plus Bmab (CapeOX/mFOLFOX6+Bmab) versus combination CapeOX/mFOLFOX6+Bmab in advanced colorectal cancer: The C-cubed (C3) study.
First Author: Hitoshi Ojima
Poster
2016 ASCO Annual Meeting
Maintenance therapy with avelumab (MSB0010718C; anti-PD-L1) vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric cancer: the phase 3 JAVELIN Gastric 100 trial.
First Author: Markus H. Moehler
Poster
2014 Gastrointestinal Cancers Symposium
The importance of sequence in rescheduling bevacizumab and chemotherapy administration in the first-line treatment of metastatic colorectal carcinoma (mCRC).
First Author: Leonidas Chelis